Biodel Posts Positive Preliminary Data on its Diabetes Drug

[Northerner]

Biodel Inc. (BIOD - Snapshot Report) announced positive preliminary data from a phase IIa study on its diabetes candidate, BIOD-531. The phase IIa Study 3-151 is comparing a concentrated insulin formulation, BIOD-531 to Eli Lilly and Company’s (LLY - Analyst Report) Humalog Mix 75/25 and Humulin R U-500 in patients suffering from type I and type II diabetes with severe insulin resistance who use at least 150 units of insulin per day or at least 100 units of insulin in a single injection.

http://www.zacks.com/stock/news/159817/biodel-posts-positive-preliminary-data-on-its-diabetes-drug